Biomarkers for pancreatic cancer and diagnostic methods
Methods and related kits for differentiating pancreatic cancer from a benign pancreatic disease. The method includes assaying a patient biological sample for a total level of CA 19-9 antigen and for a glycan level in specific mucin(s), and comparing the total level of CA 19-9 antigen and the glycan level in the specific mucin(s) to statistically validated thresholds, wherein a different level of total CA 19-9 antigen in the patient biological sample as compared to a statistically validated threshold and a different level of glycan level in the specific mucin(s) as compared to statistically validated thresholds indicate pancreatic cancer in the patient rather than a benign pancreatic disease.
1. A method for differentiating pancreatic cancer from a benign pancreatic disease, comprising the steps:
obtaining a patient biological sample from a patient having or suspected of having a pancreatic disease;
assaying the patient biological sample (a) to detect a total level of CA 19-9 antigen in the patient biological sample and (b) to detect a glycan level in MUC16 in the patient biological sample;
comparing the total level of CA 19-9 antigen in the patient biological sample to a statistically validated threshold for total CA 19-9 antigen, which statistically validated threshold for total CA 19-9 antigen is based on a total level of CA 19-9 antigen in comparable control biological samples from patients having a benign pancreatic disease; and
comparing the glycan level in the MUC16 in the patient biological sample to a statistically validated threshold for the MUC16, which statistically validated threshold for the MUC16 is based on a glycan level in the MUC16 in comparable control biological samples from patients having a benign pancreatic disease;
wherein (a) a different level of total CA 19-9 antigen in the patient biological sample as compared to the statistically validated threshold for total CA 19-9 antigen and (b) a different level of glycan level in the MUC16 in the patient biological sample as compared to the statistically validated threshold for the MUC16 indicate that the patient has pancreatic cancer rather than a benign pancreatic disease.
2. The method of claim 1 , wherein pancreatitis is the benign pancreatic disease.
3. The method of claim 1 , further comprising the step of diagnosing, pancreatic cancer in the patient.
4. The method of claim 1 , further comprising reporting the indication of pancreatic cancer to the patient or a physician.
5. The method of claim 1 , further comprising providing a treatment for pancreatic cancer to the patient.
6. The method of claim 1 , further comprising providing a monoclonal antibody to the CA-19-9 antigen and using the monoclonal antibody in assaying for both (a) the total CA 19-9 antigen in the patient biological sample and (b) the glycan level in the MUC16 in the patient biological sample.
7. The method of claim 1 , further comprising the steps of:
assaying the patient biological sample to detect a glycan level in MUC1 in the patient biological sample;
comparing the glycan level in the MUC1 in the patient biological sample to a statistically validated threshold for the MUC1, which statistically validated threshold for the MUC1 is based on a glycan level in the MUC1 in comparable control biological samples from patients having a benign pancreatic disease;
wherein (a) a different level of total CA 19-9 antigen in the patient biological sample as compared to the statistically validated threshold for total CA 19-9 antigen, (b) a different level of glycan level in the MUC16 in the patient biological sample as compared to the statistically validated threshold for the MUC16, and (c) a different level of glycan level in the MUC1 in the patient biological sample as compared to the statistically validated threshold for the MUC1 indicate that the patient has pancreatic cancer rather than a benign pancreatic disease.
8. The method of claim 7 , further comprising providing a glycan binding protein other than a monoclonal antibody to the CA 19-9 antigen and using the glycan binding protein in assaying MUC16.
9. The method of claim 8 , wherein the glycan binding protein other than the monoclonal antibody to the CA 19-9 antigen is Bauhinea Purpurea lectin (BPL).
10. The method of claim 1 , wherein the patient biological sample is plasma or serum from the patient.